AR059064A1 - Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. - Google Patents

Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.

Info

Publication number
AR059064A1
AR059064A1 ARP070100212A ARP070100212A AR059064A1 AR 059064 A1 AR059064 A1 AR 059064A1 AR P070100212 A ARP070100212 A AR P070100212A AR P070100212 A ARP070100212 A AR P070100212A AR 059064 A1 AR059064 A1 AR 059064A1
Authority
AR
Argentina
Prior art keywords
alkyl
cr9r10
aryl
heteroaryl
cycloalkyl
Prior art date
Application number
ARP070100212A
Other languages
English (en)
Inventor
Matthew Lee
Celia Dominguez
Fang-Tsao Hong
Qingyian Liu
Christopher H Fotsch
Xin Huang
Matthew Paul Bourbeau
James Thomas Rider
Seifu Tadesse
Andrew Tasker
Vellarkad N Viswa-Nadhan
Kurt Edward Weiler
George Erich Wohlhieter
Guomin Yao
Chester Chenguang Yuan
Qinping Zeng
Nianhe Han
John Gordon Allen
Xianghong Wang
Aiwen Li
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR059064A1 publication Critical patent/AR059064A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Abstract

Reivindicacion 1: Un compuesto de la formula (1) donde: A es como se muestra en la formula (2) o arilo; Y es -N(R5)R6 o -OR6; X es O, S, o -N(R7); R1 es R8, -CHR11-N(H)-R8, -CHR11-O-R8, alquinilo C2-6, hidroxialquinilo C2-6 o -C:::N; R2 es arilo o heteroarilo; R3 es -H, alquilo C1-6, que puede estar interrumpido por uno o más heteroátomos, -(CR9R10)t(arilo), -(CR9R 10)t(heteroarilo), -(CR9R10)t(cicloalquilo) o -(CR9R10)t(heterociclilo); R4 es alquilo C1-6, que puede estar interrumpido por uno o más heteroátomos, -(CR9R10)t(arilo), -(CR9R 10)t(heteroarilo), -(CR9R10)t(cicloalquilo) o -(CR9R10)t(heterociclilo); o R3 y R4, junto con el átomo de carbono al cual ambos están enlazados, se unen para formar un sistema de anillos carbocíclicos o heterocíclicos C3-10, o R4 y R7 se unen para formar un anillo heterocíclico C3-10; R5 es -H, alquilo C1-8, -C(O)(CR9R10)t)N(R7)2, -C(O)(CR9R10)t -C(O)2(CR9R10)t,-(CR9R10)t(arilo), -(CR9R10)t(heteroarilo), -(CR9R10)t(cicloalquilo) o - (CR9R10)t(heterociclilo), o R4 y R5 se unen para formar un anillo heterocíclico C3-10; R6 y R7 se seleccionan, en forma independiente, de -H, alquilo C1-8, -(alquilo C1-6)arilo, o -C(O)(alquilo C1-6), o R6 y R7, junto con los átomos a los cuales están enlazados, se unen para formar un anillo heterocíclico de 5 a 6 miembros, o R5 y R6, junto con el átomo de nitrogeno al cual están enlazados, se unen para formar un anillo heterocíclico o heteroarilo de 5 a 6 miembros; R8 es -H, alquilo C1-6, - (alquilo C1-6)arilo, arilo o heteroarilo; y R9, R10 y R11 se seleccionan, en forma independiente, de -H, alquilo C1-6 o arilo; donde n es un entero de 1 a 6; m es un entero de 0 a 2; y cada t es, en forma independiente, un entero de 0 a 3; donde cada uno de los citados alquilo, arilo, heteroarilo, cicloalquilo y fracciones heterociclilo, y anillos heterocíclicos y carbocíclicos están opcional e independientemente sustituidos por 1 a 3 sustituyentes que se seleccionan de: amino, arilo, heteroarilo, cicloalquilo o heterociclilo opcionalmente sustituido por 1 a 5 sustituyentes que se seleccionan de alcoxi C1-6, alquilo C1-6 opcionalmente sustituido por halo, arilo, halo, hidroxilo, heteroarilo, hidroxialquilo C1-6, o -NHS(O)2- (alquilo C1-6); alquilo C1-6, haloalquilo C2-6, hidroxialquilo C1-6, alcoxi C1-6, alquilo C1-6, amino, alquenilo C2-6 o alquinilo C2-6, donde cada uno de los cuales puede estar interrumpido por uno o más heteroátomos, ciano, halo, hidroxilo, nitro, o -O-arilo; o una sal farmacéuticamente aceptable, hidrato o estereoisomero de éste.
ARP070100212A 2006-01-18 2007-01-18 Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer. AR059064A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US75954606P 2006-01-18 2006-01-18

Publications (1)

Publication Number Publication Date
AR059064A1 true AR059064A1 (es) 2008-03-12

Family

ID=38180602

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100212A AR059064A1 (es) 2006-01-18 2007-01-18 Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.

Country Status (21)

Country Link
US (2) US7514566B2 (es)
EP (1) EP1981884B1 (es)
JP (1) JP5199885B2 (es)
KR (1) KR20080091369A (es)
CN (1) CN101421265A (es)
AR (1) AR059064A1 (es)
AU (1) AU2007207743B2 (es)
BR (1) BRPI0706621A2 (es)
CA (1) CA2636077C (es)
CR (1) CR10211A (es)
EA (1) EA200801716A1 (es)
ES (1) ES2389062T3 (es)
IL (1) IL192751A0 (es)
MY (1) MY149143A (es)
NO (1) NO20083572L (es)
PE (1) PE20071114A1 (es)
TW (1) TW200738657A (es)
UA (1) UA91895C2 (es)
UY (1) UY30098A1 (es)
WO (1) WO2007084391A2 (es)
ZA (1) ZA200806386B (es)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006044860A2 (en) 2004-10-18 2006-04-27 Amgen, Inc. Thiadiazole compounds and methods of use
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
CA2678036A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
CA2692713A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
AU2008276512A1 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of PKB
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
JP2011525929A (ja) * 2008-06-26 2011-09-29 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ａｋｔ活性の阻害剤
US9540322B2 (en) 2008-08-18 2017-01-10 Yale University MIF modulators
US9643922B2 (en) 2008-08-18 2017-05-09 Yale University MIF modulators
CA2733554A1 (en) * 2008-08-18 2010-02-25 Yale University Mif modulators
LT3135672T (lt) * 2008-10-10 2020-05-25 Vm Discovery, Inc. Kompozicijos ir būdai skirti gydyti alkoholio vartojimo sutrikimus, skausmą ir kitas ligas
JP5770102B2 (ja) * 2008-12-19 2015-08-26 ジェネンテック， インコーポレイテッド 複素環化合物と使用方法
EP2387570A1 (en) * 2009-01-15 2011-11-23 Amgen, Inc Fluoroisoquinoline substituted thiazole compounds and methods of use
EP2440556A1 (en) * 2009-06-10 2012-04-18 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatidylinositol 3-kinase
HRP20171415T4 (hr) 2009-06-25 2023-03-03 Alkermes Pharma Ireland Limited Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja
ES2532026T3 (es) * 2009-10-08 2015-03-23 Glaxosmithkline Llc Combinación
CA2777087C (en) * 2009-10-08 2017-10-31 Glaxosmithkline Llc Combination
CN102665720A (zh) * 2009-10-12 2012-09-12 葛兰素史密斯克莱有限责任公司 组合
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
EA027123B1 (ru) 2009-11-05 2017-06-30 Ризен Фармасьютикалз С.А. Ингибиторы киназы pi3k
KR20130038224A (ko) * 2010-03-15 2013-04-17 가부시키가이샤 구라레 티에노피리딘 유도체 및 그 제조 방법, 그리고 그것을 사용한 유기 반도체 디바이스
JP5578705B2 (ja) * 2010-03-29 2014-08-27 公益財団法人相模中央化学研究所 （アリール）ジフルオロ酢酸エステル誘導体及びその製造方法
US8383623B2 (en) * 2010-04-16 2013-02-26 Abbott Laboratories Phthalazin-(2H)-one inhibitors of kinases
WO2011130921A1 (en) * 2010-04-23 2011-10-27 Merck Sharp & Dohme Corp. Inhibitors of akt activity
EP2579872A4 (en) * 2010-04-23 2013-11-13 Merck Sharp & Dohme HAMMER OF ACT ACTIVITY
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
CN107337659A (zh) 2011-05-04 2017-11-10 理森制药股份公司 作为蛋白激酶调节剂的新颖化合物
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
CN103304468A (zh) * 2012-03-13 2013-09-18 华东师范大学 一种氧化吲哚的一锅法串联合成方法
WO2013146754A1 (ja) 2012-03-27 2013-10-03 塩野義製薬株式会社 Ｔｒｐｖ４阻害活性を有する芳香族複素５員環誘導体
WO2013173382A1 (en) 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
MY169987A (en) 2012-07-04 2019-06-19 Rhizen Pharmaceuticals Sa Selective pi3k delta inhibitors
CA2901696C (en) 2013-02-19 2021-04-13 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
WO2014160401A1 (en) * 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
CA2906538C (en) 2013-03-14 2021-02-02 Ana Gonzalez Buenrostro Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
SG10201902429PA (en) 2013-11-11 2019-04-29 Amgen Inc Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201705821XA (en) * 2015-03-02 2017-08-30 Rigel Pharmaceuticals Inc TGF-ß INHIBITORS
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
AR107840A1 (es) * 2016-03-10 2018-06-13 Astrazeneca Ab INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASA g
AU2018243770A1 (en) 2017-03-30 2019-09-19 F. Hoffmann-La Roche Ag Isoquinolines as inhibitors of HPK1
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
AU2019230014A1 (en) 2018-03-05 2020-09-17 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CA3098574A1 (en) 2018-05-04 2019-11-07 Amgen Inc. Kras g12c inhibitors and methods of using the same
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
BR112021023277A2 (pt) 2019-05-21 2022-01-04 Amgen Inc Formas em estado sólido
AU2020325115A1 (en) * 2019-08-02 2022-03-17 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
US20230028414A1 (en) 2019-12-16 2023-01-26 Amgen Inc. Dosing regimen of kras g12c inhibitor
CN111603466B (zh) * 2020-06-29 2022-07-22 江南大学 一种乙酮类化合物在制备治疗肿瘤药物中的应用
CN114014787B (zh) * 2022-01-10 2022-03-22 苏州开元民生科技股份有限公司 一种制备(2s,3r)-对甲砜基苯丝氨酸乙酯的不对称合成方法
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3591600A (en) 1969-07-07 1971-07-06 Stauffer Chemical Co 2-aminothiazole phosphates and phosphonates
GB1435139A (en) 1972-08-17 1976-05-12 Sumitomo Chemical Co Thiazole derivatives
JPS5239827B2 (es) 1973-11-08 1977-10-07
US4086239A (en) 1977-07-01 1978-04-25 Stauffer Chemical Company Thiazole bis-phosphates and phosphonates, intermediates, and insecticidal compositions and methods
DK150068C (da) 1978-06-02 1987-06-29 Pfizer Analogifremgangsmaade til fremstilling af aminothiazoler
US4297365A (en) 1978-08-04 1981-10-27 Ciba-Geigy Corporation Benzimidazoles and pharmaceutical preparations containing such compounds
US4451471A (en) 1981-03-18 1984-05-29 Ciba-Geigy Corporation Certain 2,4,5-tri-substituted thiazoles, pharmaceutical compositions containing same and methods of using same
FR2511375A1 (fr) 1981-08-17 1983-02-18 Rhone Poulenc Sante Nouveaux derives de la cephalosporine, leur preparation et les medicaments qui les contiennent
DE3630732A1 (de) 1986-09-10 1988-03-17 Bayer Ag 2-cyano-2-alkoximino-acetamide
US5232921A (en) * 1987-03-12 1993-08-03 Sanofi Thiazole derivatives active on the cholinergic system, process for obtention and pharmaceutical compositions
JPH0753666B2 (ja) 1987-09-14 1995-06-07 久光製薬株式会社 置換ジフェニルチアゾール誘導体からなる抗炎症剤
FR2636628B1 (fr) 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
US5302608A (en) 1988-11-18 1994-04-12 Takeda Chemical Industries, Ltd. Age formation inhibitors
US5145860A (en) 1989-01-05 1992-09-08 Fujisawa Pharmaceutical Co., Ltd. Thiazole compounds and pharmaceutical composition comprising the same
US5550138A (en) 1992-03-25 1996-08-27 Takeda Chemical Industries, Ltd. Condensed thiadiazole derivative, method of its production, and use thereof
KR980700077A (ko) 1994-11-29 1998-03-30 나까토미 히로타카 2-아미노티아졸유도체 및 그 염류로 이루어진 항균제 또는 살균제(Antibacterial Prepartion or Bactericide comprising 2-Aminothiazole Derivative or Salt Thereof
FR2735777B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant
US6407124B1 (en) * 1998-06-18 2002-06-18 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
EP1087951B9 (en) 1998-06-18 2006-09-13 Bristol-Myers Squibb Company Carbon substituted aminothiazole inhibitors of cyclin dependent kinases
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
EP1150565A1 (en) 1999-02-08 2001-11-07 LION bioscience AG Thiazole derivatives and combinatorial libraries thereof
AUPP873799A0 (en) 1999-02-17 1999-03-11 Fujisawa Pharmaceutical Co., Ltd. Pyridine compounds
UA71971C2 (en) 1999-06-04 2005-01-17 Agoron Pharmaceuticals Inc Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
EP1205478A4 (en) 1999-08-06 2004-06-30 Takeda Chemical Industries Ltd P38MAP KINASE INHIBITORS
JP2001114690A (ja) * 1999-08-06 2001-04-24 Takeda Chem Ind Ltd ｐ３８ＭＡＰキナーゼ阻害剤
EP1268474A2 (en) 2000-03-30 2003-01-02 Takeda Chemical Industries, Ltd. Substituted 1,3-thiazole compounds, their production and use
WO2001074793A2 (en) * 2000-04-03 2001-10-11 3-Dimensional Pharmaceuticals, Inc. Substituted thiazoles and the use thereof as inhibitors of plasminogen activator inhibitor-1
US7074934B2 (en) 2000-06-13 2006-07-11 Tularik Limited Serine protease inhibitors
GT200100147A (es) 2000-07-31 2002-06-25 Derivados de imidazol
JP4689801B2 (ja) 2000-08-09 2011-05-25 ケミプロ化成株式会社 アミノチアゾール誘導体の製造方法
JP2002053566A (ja) 2000-08-11 2002-02-19 Japan Tobacco Inc チアゾール化合物及びその医薬用途
GB0114185D0 (en) 2001-06-12 2001-08-01 Protherics Molecular Design Lt Compounds
US20040097555A1 (en) 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
AR032653A1 (es) 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
ATE315555T1 (de) 2001-05-11 2006-02-15 Pfizer Prod Inc Thiazolderivate und ihre verwendung als cdk- inhibitoren
WO2002100433A1 (en) 2001-06-11 2002-12-19 Takeda Chemical Industries, Ltd. Medicinal compositions
AR039059A1 (es) 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
JP4495963B2 (ja) * 2001-09-28 2010-07-07 サイクラセル リミテッド 抗増殖性化合物としてのｎ−（４−（４−メチルチアゾール−５−イル）ピリミジン−２−イル）−ｎ−フェニルアミン類
GB0123589D0 (en) 2001-10-01 2001-11-21 Syngenta Participations Ag Organic compounds
EP1441732A2 (en) 2001-11-08 2004-08-04 Fujisawa Pharmaceutical Co., Ltd. Thiazole derivative and pharmaceutical use thereof
EP1474141A1 (en) 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd 5-ht2b receptor antagonists
ES2292992T3 (es) * 2002-02-28 2008-03-16 F. Hoffmann-La Roche Ag Derivados de tiazol como antagonistas del receptor npy.
TWI314928B (en) 2002-02-28 2009-09-21 Novartis A 5-phenylthiazole derivatives and use as pi3 kinase inhibitors
US20040053948A1 (en) 2002-05-10 2004-03-18 Cytokinetics, Inc. Compounds, compositions and methods
FR2842523A1 (fr) 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
EP1551815A1 (en) 2002-10-09 2005-07-13 Pfizer Products Inc. Thiazole compounds for the treatment of neurodegenerative disorders
JP2006514684A (ja) 2002-10-30 2006-05-11 バーテックス　ファーマシューティカルズ　インコーポレイテッド Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物
GB0226583D0 (en) 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
FR2850380B1 (fr) 2003-01-23 2006-07-07 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd ７員複素環誘導体
TW200519106A (en) * 2003-05-02 2005-06-16 Novartis Ag Organic compounds
ATE536353T1 (de) * 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
KR20060088537A (ko) 2003-09-06 2006-08-04 버텍스 파마슈티칼스 인코포레이티드 Ａｔｐ-결합 카세트 수송체의 조절자
GB0327380D0 (en) 2003-11-25 2003-12-31 Cyclacel Ltd Method
GB0329275D0 (en) 2003-12-18 2004-01-21 Merck Sharp & Dohme Therapeutic treatment
SI1709019T1 (sl) 2004-01-12 2007-10-31 Serono Lab Derivati tiazola in uporaba le-teh
EP1709018B1 (fr) 2004-01-16 2011-07-20 Sanofi-Aventis Derives d'acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
WO2005073226A1 (fr) 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole, leur preparation et leur application en therapeutique
JP2007526324A (ja) * 2004-03-02 2007-09-13 スミスクライン・ビーチャム・コーポレイション Ａｋｔ活性のある阻害剤
AP2379A (en) 2004-03-23 2012-03-08 Pfizer Prod Inc Imidazole compounds for the treatment of neurodegenerative disorders.
CN1989131A (zh) 2004-03-30 2007-06-27 希龙公司 取代的噻吩衍生物用作抗癌药
CA2563374A1 (en) * 2004-04-27 2005-12-08 Research Development Foundation Antagonism of tgf-.beta.superfamily receptor signaling
EP1758920A1 (en) 2004-05-21 2007-03-07 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
GB0411791D0 (en) 2004-05-26 2004-06-30 Cyclacel Ltd Compounds
BRPI0515012A (pt) 2004-08-13 2008-07-01 Genentech Inc substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
WO2006044860A2 (en) 2004-10-18 2006-04-27 Amgen, Inc. Thiadiazole compounds and methods of use
SE0402735D0 (sv) 2004-11-09 2004-11-09 Astrazeneca Ab Novel compounds
US20060178388A1 (en) 2005-02-04 2006-08-10 Wrobleski Stephen T Phenyl-substituted pyrimidine compounds useful as kinase inhibitors
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
KR101386282B1 (ko) 2005-06-17 2014-04-17 아포지 바이오테크놀로지 코포레이션 스핑고신 키나제 저해제
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
DE102005048072A1 (de) 2005-09-24 2007-04-05 Bayer Cropscience Ag Thiazole als Fungizide
WO2007066805A1 (ja) 2005-12-09 2007-06-14 Meiji Seika Kaisha, Ltd. リンコマイシン誘導体およびこれを有効成分とする抗菌剤
US7595398B2 (en) 2005-12-12 2009-09-29 Smithkline Beecham Corporation N-(5-membered aromatic ring)-amido anti-viral compounds
JP2009528266A (ja) 2006-01-18 2009-08-06 シェーリング コーポレイション カンナビノイド受容体修飾因子
EP1981884B1 (en) * 2006-01-18 2012-06-13 Amgen, Inc Thiazole compounds as protein kinase b (pkb) inhibitors
AU2007207052B2 (en) 2006-01-18 2012-07-12 F. Hoffmann-La Roche Ag CIS-4, 5-biaryl-2-heterocyclic-imidazolines as MDM2 inhibitors
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
JP2009525960A (ja) 2009-07-16
UY30098A1 (es) 2007-10-31
IL192751A0 (en) 2009-02-11
NO20083572L (no) 2008-10-17
US8084479B2 (en) 2011-12-27
EP1981884A2 (en) 2008-10-22
JP5199885B2 (ja) 2013-05-15
US7514566B2 (en) 2009-04-07
ZA200806386B (en) 2009-11-25
EP1981884B1 (en) 2012-06-13
ES2389062T3 (es) 2012-10-22
UA91895C2 (en) 2010-09-10
US20090270445A1 (en) 2009-10-29
CA2636077A1 (en) 2007-07-26
CN101421265A (zh) 2009-04-29
AU2007207743A1 (en) 2007-07-26
CR10211A (es) 2008-10-03
CA2636077C (en) 2012-01-03
PE20071114A1 (es) 2008-01-10
AU2007207743B2 (en) 2010-07-08
WO2007084391A3 (en) 2008-03-20
BRPI0706621A2 (pt) 2011-04-05
MY149143A (en) 2013-07-15
KR20080091369A (ko) 2008-10-10
US20070173506A1 (en) 2007-07-26
TW200738657A (en) 2007-10-16
EA200801716A1 (ru) 2009-04-28
WO2007084391A2 (en) 2007-07-26

Similar Documents

Publication Publication Date Title
AR059064A1 (es) Compuestos de tiazol, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades mediadas por la proteina quinasa b(pkb), tales como cancer.
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20181298A1 (es) Inhibidores de bromodominio bivalentes y usos de los mismos
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
CU24393B1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
AR109295A1 (es) Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina
AR082885A1 (es) Compuestos y composiciones para la inhibicion de nampt
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
AR100438A1 (es) Pirazolopiridinas y pirazolopirimidinas
PE20190337A1 (es) NUEVOS DERIVADOS DE PIRROLO [2,3-d]PIRIMIDA, UN PROCESO PARA SU PREPARACION Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
PE20220567A1 (es) Nuevos derivados piperidinilo, un proceso para su preparacion y composiciones farmaceuticas que los contienen
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
AR049388A1 (es) Heterociclos como inhibidores de aldosterona sintasa
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
AR062360A1 (es) Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa
AR085960A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
AR077695A1 (es) Derivados de pirimidina como inhibidores del factor ixa
AR064454A1 (es) Derivados de pirazol con efecto inhibitorio de fgfr, metodos para su sintesis, composicion farmaceutica que los comprende, un proceso para la preparacion de la misma y su uso en la fabricacion de un medicamento para el tratamiento del cancer.
AR059895A1 (es) Derivados biciclicos de acidos carboxilicos que resultan de utilidad para tratar trastornos metabolicos
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
AR057380A1 (es) Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
AR075975A1 (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintetasa quinasa 3
MX2010000658A (es) Derivados de pirimidina 934.
AR094762A1 (es) Compuestos de hexahidropirano[3,4-d][1,3]tiazin-2-amina sustituida con heteroarilo
AR084515A1 (es) Derivados heterociclicos nitrogenados, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades asociadas al sistema nervioso central tales como parkinson y alzheimer, entre otras

Legal Events

Date Code Title Description
FB Suspension of granting procedure